Roble Belko & Company Inc cut its holdings in Biogen Inc. (NASDAQ:BIIB) by 18.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,138 shares of the biotechnology company’s stock after selling 250 shares during the period. Roble Belko & Company Inc’s holdings in Biogen were worth $356,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Biogen by 2.3% during the second quarter. BlackRock Inc. now owns 18,107,358 shares of the biotechnology company’s stock worth $4,913,612,000 after purchasing an additional 415,099 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Biogen by 1.3% during the second quarter. Vanguard Group Inc. now owns 14,534,827 shares of the biotechnology company’s stock worth $3,944,171,000 after buying an additional 182,337 shares during the last quarter. State Street Corp grew its holdings in shares of Biogen by 1.5% during the second quarter. State Street Corp now owns 9,721,312 shares of the biotechnology company’s stock worth $2,637,973,000 after buying an additional 140,929 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of Biogen by 4.0% during the first quarter. Clearbridge Investments LLC now owns 9,121,025 shares of the biotechnology company’s stock worth $2,493,871,000 after buying an additional 351,224 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Biogen by 10.1% during the second quarter. FMR LLC now owns 6,104,026 shares of the biotechnology company’s stock worth $1,656,390,000 after buying an additional 561,436 shares during the last quarter. Institutional investors own 88.28% of the company’s stock.

BIIB has been the topic of a number of analyst reports. Citigroup Inc. lowered Biogen from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd. Mizuho set a $400.00 price objective on Biogen and gave the company a “buy” rating in a report on Monday, November 13th. Vetr lowered Biogen from a “strong-buy” rating to a “buy” rating and set a $319.53 price objective on the stock. in a report on Wednesday, August 23rd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $300.00 price objective on shares of Biogen in a report on Thursday, October 12th. Finally, Robert W. Baird reiterated a “hold” rating and set a $290.00 price target on shares of Biogen in a research report on Friday, August 25th. Twelve analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $341.89.

WARNING: “Roble Belko & Company Inc Has $356,000 Holdings in Biogen Inc. (BIIB)” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/22/roble-belko-company-inc-has-356000-holdings-in-biogen-inc-biib.html.

Biogen Inc. (NASDAQ:BIIB) traded down $0.53 on Wednesday, reaching $308.53. 373,999 shares of the company traded hands, compared to its average volume of 1,504,810. The firm has a market capitalization of $65,090.00, a price-to-earnings ratio of 14.33, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. Biogen Inc. has a 52-week low of $244.28 and a 52-week high of $348.84. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46.

Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The firm had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the prior year, the firm earned $5.19 EPS. Biogen’s quarterly revenue was up 4.1% on a year-over-year basis. equities analysts anticipate that Biogen Inc. will post 22.03 EPS for the current year.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.